Last 7 days
-0.3%
Last 30 days
-24.3%
Last 90 days
-15.3%
Trailing 12 Months
-27.3%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
SYK | 103.1B | 18.4B | 6.02% | 5.19% | 43.7 | 5.59 | 7.84% | 18.25% |
ISRG | 88.4B | 6.2B | 9.31% | -11.96% | 66.85 | 14.21 | 8.97% | -22.43% |
BSX | 69.2B | 12.7B | 2.81% | 11.10% | 99.12 | 5.46 | 6.68% | -32.95% |
BDX | 68.6B | 19.0B | 2.19% | -5.22% | 42.6 | 3.61 | -0.43% | -8.78% |
EW | 49.2B | 5.4B | 6.12% | -27.99% | 32.34 | 9.15 | 2.86% | 1.25% |
MID-CAP | ||||||||
SWAV | 7.2T | 489.7M | 16.25% | 13.06% | 82.2K | 16.8K | 106.51% | 2464.23% |
PEN | 10.4B | 847.1M | 3.66% | 36.84% | -5.2K | 12.31 | 13.32% | -137.89% |
GMED | 5.2B | 1.0B | -9.17% | -24.82% | 30.22 | 5.09 | 6.76% | 24.45% |
IRTC | 3.6B | 410.9M | 3.83% | -15.78% | -30.64 | 8.66 | 27.29% | -14.60% |
TNDM | 2.7B | 801.2M | 11.07% | -63.68% | -28.28 | 3.34 | 14.00% | -707.69% |
SMALL-CAP | ||||||||
ATEC | 1.6B | 350.9M | 7.57% | 51.19% | -10.79 | 4.68 | 44.26% | -5.42% |
SILK | 1.6B | 138.6M | -27.43% | 0.81% | -28.66 | 11.37 | 36.62% | -10.44% |
AVNS | 1.3B | 820.0M | 0.91% | -12.65% | 26.12 | 1.61 | 10.13% | 701.59% |
CSII | 828.4M | 239.8M | 0.81% | -4.01% | -21.88 | 3.45 | -4.74% | -31.15% |
Income Statement (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -0.9% | 537,840 | 542,624 | 545,232 | 537,883 | 535,031 |
Gross Profit | -0.9% | 422,973 | 426,958 | 429,109 | 421,664 | 420,154 |
Operating Expenses | 3.1% | 512,496 | 496,901 | 482,993 | 466,715 | 464,487 |
S&GA Expenses | 6.5% | 173,658 | 163,011 | 154,196 | 143,584 | 137,057 |
R&D Expenses | -1.0% | 206,085 | 208,196 | 204,381 | 197,621 | 201,303 |
EBITDA | -10.9% | -71,181 | -64,170 | -51,211 | -41,264 | - |
EBITDA Margin | -11.9% | -0.13* | -0.12* | -0.09* | -0.08* | - |
Earnings Before Taxes | -9.3% | -81,846 | -74,861 | -61,977 | -51,856 | -52,075 |
EBT Margin | -10.3% | -0.15* | -0.14* | -0.11* | -0.10* | - |
Interest Expenses | -59.4% | 41.00 | 101 | 101 | 101 | 101 |
Net Income | -13.3% | -92,534 | -81,689 | -68,237 | -58,870 | -58,351 |
Net Income Margin | -14.3% | -0.17* | -0.15* | -0.13* | -0.11* | - |
Free Cahsflow | -52.1% | 9,430 | 19,698 | 24,084 | 36,007 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 1.5% | 1,192 | 1,174 | 1,163 | 1,150 | 1,139 |
Current Assets | 0.8% | 1,112 | 1,102 | 1,095 | 1,081 | 1,074 |
Cash Equivalents | -52.7% | 115 | 244 | 368 | 192 | 209 |
Inventory | 9.6% | 29.00 | 27.00 | 30.00 | 29.00 | 24.00 |
Net PPE | 9.9% | 33.00 | 30.00 | 27.00 | 25.00 | 23.00 |
Liabilities | 3.0% | 750 | 729 | 721 | 714 | 729 |
Current Liabilities | 12.5% | 159 | 141 | 135 | 128 | 143 |
Long Term Debt | - | 562 | - | - | - | - |
LT Debt, Non Current | 0.1% | 566 | 565 | 564 | 563 | 562 |
Shareholder's Equity | -0.9% | 441 | 445 | 442 | 436 | 410 |
Retained Earnings | -5.0% | -778 | -741 | -714 | -690 | -685 |
Additional Paid-In Capital | 2.8% | 1,222 | 1,189 | 1,158 | 1,128 | 1,100 |
Accumulated Depreciation | - | 22.00 | - | - | - | - |
Shares Outstanding | 0.2% | 105 | 105 | 105 | 104 | 104 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -37.0% | 31.00 | 49.00 | 51.00 | 61.00 | 83.00 |
Share Based Compensation | 7.4% | 107 | 100 | 99.00 | 101 | 95.00 |
Cashflow From Investing | 72.6% | -139 | -510 | -58.04 | -216 | -144 |
Cashflow From Financing | -1.5% | 15.00 | 16.00 | 15.00 | 21.00 | 26.00 |
99.6%
80%
43.9%
Y-axis is the maximum loss one would have experienced if Novocure was unfortunately bought at previous high price.
24.1%
22.3%
-3.8%
FIve years rolling returns for Novocure.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-23 | ETF MANAGERS GROUP, LLC | sold off | -100 | -3,751,000 | - | -% |
2023-03-17 | American Portfolios Advisors | reduced | -4.76 | 180 | 4,559 | -% |
2023-03-10 | BAILLIE GIFFORD & CO | reduced | -0.56 | -27,137,200 | 650,163,000 | 0.68% |
2023-03-07 | Nordwand Advisors, LLC | new | - | 111,125,000 | 111,125,000 | 13.86% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -85.97 | -600,000 | 93,000 | -% |
2023-03-03 | TIAA, FSB | unchanged | - | -7,718 | 215,282 | -% |
2023-02-28 | Voya Investment Management LLC | added | 8.68 | 1,100,570 | 23,496,600 | 0.03% |
2023-02-22 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | unchanged | - | -241,000 | 6,733,000 | 0.07% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | unchanged | - | -330 | 14,670 | -% |
2023-02-21 | MACQUARIE GROUP LTD | added | 13.25 | 502,148 | 5,886,150 | 0.01% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 13, 2023 | capital international investors | 7.8% | 8,155,909 | SC 13G/A | |
Feb 13, 2023 | capital world investors | 12.3% | 12,899,395 | SC 13G/A | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.10% | 9,547,336 | SC 13G/A | |
Jan 31, 2023 | blackrock inc. | 7.2% | 7,605,425 | SC 13G/A | |
Jan 23, 2023 | baillie gifford & co | 8.45% | 8,863,842 | SC 13G/A | |
Apr 11, 2022 | fmr llc | - | 0 | SC 13G/A | |
Feb 11, 2022 | capital world investors | 12.3% | 12,723,214 | SC 13G/A | |
Feb 11, 2022 | capital international investors | 11.1% | 11,531,075 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 1.42 -97.54% | 2.29 -96.04% | 4.40 -92.38% | 8.72 -84.91% | 17.51 -69.69% |
Current Inflation | 1.37 -97.63% | 2.14 -96.30% | 3.97 -93.13% | 7.67 -86.72% | 15.15 -73.78% |
Very High Inflation | 1.31 -97.73% | 1.96 -96.61% | 3.46 -94.01% | 6.44 -88.85% | 12.43 -78.48% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 07, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-07 | Leonard Frank X | sold | -625,205 | 75.1629 | -8,318 | president, cns cancers us |
2023-03-03 | GROENHUYSEN WILHELMUS CM | acquired | - | - | 51,986 | chief operating officer |
2023-03-03 | Weinberg Uri | acquired | - | - | 32,766 | chief innovation officer |
2023-03-03 | Shah Pritesh | sold | -1,631,410 | 76.1594 | -21,421 | chief growth officer |
2023-03-03 | Cordova Ashley | acquired | - | - | 11,808 | chief financial officer |
2023-03-03 | Burke William Patrick | sold | -45,162 | 76.1594 | -593 | chief human resources officer |
2023-03-03 | Leonard Frank X | acquired | - | - | 11,808 | president, cns cancers us |
2023-03-03 | Leonard Frank X | sold | -159,859 | 77.6391 | -2,059 | president, cns cancers us |
2023-03-03 | GROENHUYSEN WILHELMUS CM | sold | -1,952,350 | 76.1594 | -25,635 | chief operating officer |
2023-03-03 | Shah Pritesh | acquired | - | - | 47,182 | chief growth officer |
Consolidated statements of operations - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | |||
Net revenues | $ 537,840 | $ 535,031 | $ 494,366 |
Cost of revenues | 114,867 | 114,877 | 106,501 |
Gross profit | 422,973 | 420,154 | 387,865 |
Operating costs and expenses: | |||
Research, development and clinical studies | 206,085 | 201,303 | 132,010 |
Sales and marketing | 173,658 | 137,057 | 118,017 |
General and administrative | 132,753 | 126,127 | 107,437 |
Total operating costs and expenses | 512,496 | 464,487 | 357,464 |
Operating income (loss) | (89,523) | (44,333) | 30,401 |
Financial (expenses) income, net | 7,677 | (7,742) | (12,299) |
Income (loss) before income taxes | (81,846) | (52,075) | 18,102 |
Income tax | 10,688 | 6,276 | (1,706) |
Net income (loss) | $ (92,534) | $ (58,351) | $ 19,808 |
Basic net income (loss) per ordinary share (in usd per share) | $ (0.88) | $ (0.56) | $ 0.20 |
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares) | 104,660,476 | 103,433,274 | 100,930,866 |
Diluted net income (loss) per ordinary share (in usd per share) | $ (0.88) | $ (0.56) | $ 0.18 |
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares) | 104,660,476 | 103,433,274 | 108,877,648 |
Consolidated balance sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 115,326 | $ 208,802 |
Short-term investments | 854,099 | 728,898 |
Restricted cash | 508 | 807 |
Trade receivables, net | 86,261 | 93,567 |
Receivables and prepaid expenses | 25,959 | 17,025 |
Inventories | 29,376 | 24,427 |
Total current assets | 1,111,529 | 1,073,526 |
Long-term assets: | ||
Property and equipment, net | 32,678 | 22,693 |
Field equipment, net | 12,684 | 12,923 |
Right-of-use assets | 23,596 | 18,267 |
Other long-term assets | 11,161 | 12,086 |
Total long-term assets | 80,119 | 65,969 |
Total assets | 1,191,648 | 1,139,495 |
Current liabilities: | ||
Trade payables | 85,197 | 72,600 |
Other payables, lease liabilities and accrued expenses | 73,580 | 70,002 |
Total current liabilities | 158,777 | 142,602 |
Long-term liabilities: | ||
Long-term debt, net | 565,509 | 562,216 |
Deferred revenues | 2,878 | 6,477 |
Long term leases | 18,762 | 12,997 |
Employee benefit liabilities | 4,404 | 4,543 |
Other long-term liabilities | 148 | 166 |
Total long-term liabilities | 591,701 | 586,399 |
Total liabilities | 750,478 | 729,001 |
Commitments and contingencies | ||
Shareholders’ equity: | ||
Ordinary shares - No par value, Unlimited shares authorized; Issued and outstanding: 105,049,411 shares and 103,971,263 shares at December 31, 2022 and December 31, 2021 respectively; | 0 | 0 |
Additional paid-in capital | 1,222,063 | 1,099,589 |
Accumulated other comprehensive income (loss) | (2,433) | (3,169) |
Retained earnings (accumulated deficit) | (778,460) | (685,926) |
Total shareholders’ equity | 441,170 | 410,494 |
Total liabilities and shareholders’ equity | $ 1,191,648 | $ 1,139,495 |